City of Hope Medical Center: clinical-trial pipeline
City of Hope Medical Center is the sponsor of 673 clinical trials in ClinicalTrials.gov and the EU CTIS portal; 327 are not yet finished and 5 were first posted in the last 90 days. Source: Arcadium Data, data as of .
Open trials327
Phase 2/3 and 38
Countries11
New in 90 days5
Trials by phase
| Phase | Trials |
|---|---|
| Not applicable | 231 |
| Phase 1 | 218 |
| Phase 2 | 158 |
| Phase 1/2 | 39 |
| Early phase 1 | 18 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Trials by status
| Status | Trials |
|---|---|
| Completed | 240 |
| Recruiting | 155 |
| Active, not recruiting | 149 |
| Withdrawn or not authorised | 52 |
| Terminated | 30 |
| Not yet recruiting | 23 |
| Suspended or halted | 22 |
| Unknown | 2 |
Condition areas
| Area | Trials |
|---|---|
| Oncology | 627 |
| Gastroenterology and liver | 65 |
| Nephrology and urology | 64 |
| Rare and genetic diseases | 59 |
| Haematology | 39 |
| Infectious disease and vaccines | 31 |
| Women's health and obstetrics | 28 |
| Metabolic and endocrine (diabetes, obesity) | 22 |
| Dermatology | 17 |
| Immunology and rheumatology | 14 |
| Psychiatry and mental health | 14 |
| Musculoskeletal | 11 |
Countries
| Country | Trials |
|---|---|
| United States | 624 |
| Japan | 11 |
| Spain | 4 |
| Canada | 3 |
| China | 2 |
| Italy | 2 |
| Colombia | 1 |
| South Korea | 1 |
| Mexico | 1 |
| Peru | 1 |
| Puerto Rico | 1 |
Latest changes
| Day | Change | Trial |
|---|---|---|
| 2026-09-25 | New trial posted | CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and S… |
| 2026-09-15 | New trial posted | Prehabilitation for Improving Outcomes in Breast Cancer Patients Undergoing Neoadjuvant S… |
| 2026-09-10 | New trial posted | Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /… |
| 2026-08-27 | New trial posted | Testing the Effects of Exercise on Colorectal Cancer Development After Treatment With Pel… |
| 2026-08-27 | New trial posted | FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Pa… |
Open trials
The 25 most recently changed open trials.
| Registry id | Title | Phase | Status | Countries |
|---|---|---|---|---|
| NCT05225363 | Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ov… | Phase 1 | Recruiting | United States |
| NCT07395050 | Autologous CD6-CAR Treg Cells for Patients With Stage 3 Type 1 Diabetes | Early phase 1 | Not yet recruiting | United States |
| NCT07363408 | Ivonescimab and ADG126, Alone, and in Combination With Leucovorin and Fluorouracil or FOLFIRI Regimen for the… | Phase 1 | Not yet recruiting | United States |
| NCT05672251 | Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym… | Phase 2 | Recruiting | United States |
| NCT00544830 | Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | Phase 2 | Active, not recruiting | United States |
| NCT00609791 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic… | Phase 2 | Active, not recruiting | United States |
| NCT04177004 | Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Underg… | Phase 1 | Active, not recruiting | United States |
| NCT07210086 | Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-direct… | Phase 2 | Recruiting | United States |
| NCT06815003 | Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Ver… | Phase 2 | Recruiting | United States |
| NCT05245786 | An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in… | Early phase 1 | Active, not recruiting | United States |
| NCT07612085 | A Wearable Biosensor Patch for Non-Invasive Monitoring for Patients Undergoing Abdominal or Chest Surgery | Not applicable | Not yet recruiting | United States |
| NCT05376878 | An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Bra… | Phase 4 | Recruiting | United States |
| NCT07125729 | Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Color… | Not applicable | Recruiting | United States |
| NCT07288034 | Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-li… | Phase 2 | Recruiting | United States |
| NCT04783415 | Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | Phase 2 | Active, not recruiting | United States |
| NCT04788095 | App-Based Mindfulness Intervention for the Improvement of Quality of Life in Patients With Metastatic Renal C… | Not applicable | Active, not recruiting | United States |
| NCT05222984 | Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Pre… | Phase 1 | Active, not recruiting | United States |
| NCT07775534 | Tear Fluid for the Detection of Tumor-associated Extracellular Vesicles in Glioblastoma Patients | Not applicable | Recruiting | United States |
| NCT07235501 | Kinetic Analysis of Immune Cells in Blood and Chronic Graft-Versus-Host Disease-Affected Tissues After Alloge… | Not applicable | Recruiting | United States |
| NCT05162976 | CC-486 and Nivolumab for the Treatment of Hodgkin Lymphoma Refractory to PD-1 Therapy or Relapsed | Phase 1 | Active, not recruiting | United States |
| NCT04537871 | Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study | Not applicable | Active, not recruiting | United States |
| NCT06454383 | Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | Phase 1 | Recruiting | United States |
| NCT06675136 | Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With… | Phase 1 | Recruiting | United States |
| NCT06112847 | Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma | Phase 2 | Active, not recruiting | United States |
| NCT05672147 | CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | Phase 1 | Recruiting | United States |
All sponsors: clinical-trial pipeline by sponsor.
Track a sponsor's pipeline
The API returns the same trials by sponsor website, phase, status, condition and country with a change feed, joined to hiring and public contract awards. Try it without a key on one sponsor.
Sources: ClinicalTrials.gov (U.S. National Library of Medicine, public domain) and the EU Clinical Trials Information System public portal (European Medicines Agency), data as of 2026-10-25. A trial that one register cites in the other is shown once. Organisation-level data only: investigators, contact persons and site names are not stored, and a sponsor that could be a private person is withheld. Sponsor-to-website matches are made by name and can be wrong; check the register before relying on a record. Independent of the NLM, NIH and EMA.
Cite as: Arcadium Data, "City of Hope Medical Center clinical trials: 327 open, 8 in phase 3", https://arcadiumdata.io/clinical-trials/sponsor/city-of-hope-medical-center/, data as of 2026-10-25.